Company Overview of Kiadis Pharma B.V.
Kiadis Pharma B.V., a clinical stage biopharmaceutical company, develops life-saving therapies for blood cancer patients in the United States and Europe. The company focuses on the development of a cellular therapeutic that enables partially mismatched donor stem cell transplants from family members in blood cancer patients. It offers ATIR, a cell-based medicinal product that facilitates early immune system recovery without causing life-threatening graft-versus-host-disease when administered as an adjunctive to a haploidentical stem cell transplantation. Kiadis Pharma B.V. was formerly known as Kiadis B.V. and changed its name to Kiadis Pharma B.V. in 2006. The company was founded in 1997 an...
Amsterdam, 1114 AA
Founded in 1997
Key Executives for Kiadis Pharma B.V.
Chief Medical Officer and Senior Vice President
Corporate Secretary and General Counsel
Compensation as of Fiscal Year 2014.
Kiadis Pharma B.V. Key Developments
Kiadis Pharma B.V. Presents at BioEquity Europe 2015, May-19-2015 05:20 PM
May 8 15
Kiadis Pharma B.V. Presents at BioEquity Europe 2015, May-19-2015 05:20 PM. Venue: InterContinental Vienna, Vienna, Austria.
Kiadis Pharma B.V. Presents at BioCapital Europe 2015, Mar-26-2015 03:20 PM
Mar 23 15
Kiadis Pharma B.V. Presents at BioCapital Europe 2015, Mar-26-2015 03:20 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.
Kiadis Pharma B.V. Announces Positive Interim Data from Ongoing Phase II Clinical Study with ATIRTM
Dec 9 14
Kiadis Pharma B.V. announced positive interim data from the ongoing Phase II clinical study with its product ATIRTM. ATIRTM is a cell-based product designed to enable stem cell transplantations from partially matched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. The Phase II study is an international multi-center study in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), will be enrolled and treated with ATIRTM as part of the transplant regimen. The primary endpoint of the study is the rate of Transplant Related Mortality (TRM) at 6 months after hematopoietic stem cell transplantation (HSCT). Data from the pre-specified interim analysis of the first 10 patients showed only 2 cases of TRM at 6 months post-HSCT and both TRM cases resulted from a viral infection. Overall, 6 out of the 10 patients were completely free from severe infections (grade 3-5) after ATIRTM administration and up to 6 months after the transplant. These data confirm the safety and efficacy of ATIRTM administration with no grade III-IV (life- threatening) acute Graft versus Host Disease (GvHD) occurring, despite the fact that no prophylactic immune suppressants were used. Only a limited number of grade I-II GvHD events were reported, all of which were treated successfully. Furthermore, no relapses were reported in any of the first 10 patients, with 4 out of the 10 patients in follow-up for more than one year at the time of the interim analysis. These data are in line with the data previously reported from Kiadis Pharma's Phase I/II study with 19 patients. The current study is progressing well with further enrollment of patients in Canada (Hôpital Maisonneuve-Rosemont (Montreal), Juravinski Hospital and Cancer Centre (Hamilton) and Princess Margaret Cancer Centre (Toronto)), Belgium (University Hospitals Leuven, AZ Sint Jan (Bruges) and Institut Jules Bordet (Brussels)) and Germany (University Hospital of Würzburg).
Similar Private Companies By Industry
Recent Private Companies Transactions
October 30, 2014
Most Searched Private Companies
Sponsored Financial Commentaries